Revenue
Margin
Demand
Guidance
Tone
Event Participants
Executives (4)
Raj Gupta, Pankaj Kedia, Nilesh Koul, Rohit Narang
Analysts (7)
Aditya, Harsh, Kumar, Nilesh, Sanil Jain, Sanjesh, Rohit Sinha
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Carbon black sales volume | 153,530 MT | Steady YoY; domestic +15% offset by deliberate export-to-domestic reallocation |
| Domestic carbon black volume | 102,985 MT | +15% YoY; steady demand across key segments plus some customer inventory building |
| International carbon black volume | 50,528 MT | Down YoY; freight-driven diversion to domestic spot; Europe ~16,000 MT, US ~4,800 MT |
| Specialty carbon black volume | 19,748 MT | +23% YoY; ~70% exported; rich product mix and increasing customer acceptance |
| Aquapharm volume | 22,985 MT | Application-specific solutions +10% YoY; oil & gas −35% YoY but +50% QoQ; home care/water marginally lower YoY |
| Consolidated revenue | ₹2,474 crores | +17% YoY; higher crude pass-through and strong spot realizations |
| Consolidated EBITDA | ₹400 crores | +23% YoY; includes ~₹70 crores low-cost inventory gains |
| Consolidated PAT | ₹155 crores | +65% YoY; aided by power EBIT improvement and better carbon black realizations |
| Carbon black EBITDA per ton | ₹22,900 | Elevated vs normalized FY27 guidance of ₹16,500–17,000/ton; includes inventory gains |
| Aquapharm EBITDA | ₹47 crores | EBITDA/kg ~₹20,000 vs ₹19,500 in Q1 FY26; considered sustainable on full-year basis |
| Power generation | 217 million units | External sales 113 million units; realization rose from ₹3.66 to ₹5.39/unit, lifting EBIT to ~₹110 crores |
| Installed carbon black capacity | 900,000 MTPA | 20,000 MTPA specialty line at Mundra commissioned in Q1 FY27 |
| Brent crude average | $97/bbl | vs $78/bbl in Q4 FY26; drove CBFS costs up and created inventory gains |
Geographic & Segment Commentary
- Domestic Carbon Black: Volumes grew 15% YoY to 102,985 MT on steady demand across key segments, aided by customer inventory building. Management noted customers have since adopted a more cautious procurement stance, expected to temporarily affect Q2 volumes.
- International Carbon Black: Volumes of 50,528 MT were deliberately diverted to the domestic spot market where realizations were more attractive, as elevated freight costs weighed on export margins. Strategic export customers were fully serviced to protect long-term relationships; growth flows expected Q2–Q4 as freight normalizes.
- Specialty Carbon Black: Volumes grew 23% YoY to 19,748 MT on rich product mix and deeper customer penetration; ~70% of specialty volumes are exported and were unaffected by supply chain disruptions. The new 20,000 MTPA Mundra line raised total installed capacity to 900,000 MTPA.
- Power: Generated 217 million units with external sales of 113 million units at improved realization of ₹5.39/unit vs ₹3.66 in Q4 FY26, driving EBIT to ~₹110 crores.
- Aquapharm: Volumes of 22,985 MT, revenue of ₹394 crores, and EBITDA of ₹47 crores. Oil & gas (−35% YoY, +50% QoQ) shows turnaround momentum; green chelates order booking is ahead of capacity; desalination demand strong in Gulf region with a new three-year anti-scaling contract secured.
Company-Specific & Strategic Commentary
- Structural trade tailwinds: India–US trade deal has sharply reduced tariffs on Indian exports; India–EU FTA (concluded January 2026) is progressing through ratification, including elimination of the 4.5% EU import duty on Indian tires. India–UK CETA, EFTA, Oman, and New Zealand agreements further broaden India's preferential market access. Indian carbon black now faces lower US tariffs than Chinese and Middle East origins, driving customer diversification interest.
- Russian supply contraction: Ukrainian strikes have hit all major Russian refineries, cutting refining throughput and CBFS exports; Russian carbon black exports have contracted sharply on top of existing EU sanctions. This creates durable white space for PCBL in Europe, Americas, and other premium markets.
- Battery materials platform: Nanovace silicon-anode pilot plant at Palej received consent to operate; equipment-level trials underway with customer sampling expected from August. A 1,000 MTPA superconductive specialty black facility in Palej is commissioned with market development across battery, conductive polymer, and electronics applications; acetylene black phase-1 engineering completed with technology collaborator. R&D hubs now span India, Australia, and Europe.
- Cost optimization: ₹200–250 crores savings program over the next 4–6 quarters remains on track via feedstock diversification and yield enhancement. Coal tar distillation project business plan is being finalized, with CapEx approval expected this quarter; raw material tie-ups for planned capacities have been evaluated.
- Aquapharm strategic initiatives: Green chelates order booking is running ahead of capacity, with qualifications progressing at P&G, Reckitt, and Henkel and a new facility under discussion; oil & gas expansion targets new US geographies (New Mexico approvals obtained) and Latin America (Venezuela, Mexico); backward integration and vendor diversification being evaluated for key raw materials. Rohit Narang (ex-Eastman Chemical) has taken over as CEO.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Carbon black EBITDA per ton (FY27) | 14–15% improvement over FY26 average (~₹16,500–17,000/ton) | Q1 achieved ₹22,900 with ~₹70 crores inventory gains; ₹40–50 crores expected to reverse in Q2; pricing discipline aims to hold gross margins at ₹36–38/kg |
| Volume growth (FY27) | High single-digit maintained | Q2 customer destocking is a timing effect, not demand destruction; management constructive on Q3–Q4 |
| Carbon black international volumes | Growth flows from Q2–Q4 FY27 | New annual contracts, particularly in US, at advanced negotiation; freight normalization plus tariff/FTA tailwinds underpin growth |
| CapEx | ~₹300 crores ± ₹50 crores | Largely maintenance and efficiency spends; only ~₹100 crores strategic; Andhra greenfield spend largely shifts to FY28 |
| Cost savings program | ₹200–250 crores over next 4–6 quarters | Feedstock diversification and yield enhancement; beginning to reflect in results |
| US tariff refund | ₹40–45 crores within 2–4 weeks | Covers PCBL and Aquapharm; accounting treatment (topline vs other income) under discussion with auditors |
| Aquapharm FY27 | Better FY27 led by volume growth | Q2 may see inventory-related EBITDA dip; previously guided ₹75 crore EBITDA exit run-rate deferred until new CEO's action plan is finalized |
Risks & Constraints
| Risk | Context |
|---|---|
| Geopolitical / crude volatility | Brent averaged $97/bbl vs $78/bbl in Q4 FY26; West Asia conflict persists, keeping logistics erratic and prices high. Management expects volatility to continue through coming quarters, with partial freight recovery only. |
| Inventory gain reversal | Q1 included ~₹70 crores of low-cost inventory gains; ₹40–50 crores may reverse in Q2 as crude-related cost positions normalize. |
| Q2 volume softness | Customers have adopted cautious procurement with destocking expected to temporarily dampen Q2 volumes. Management classifies this as a timing effect, not demand destruction. |
| Aquapharm oil & gas exposure | Segment fell 35% YoY in Q1; crude price volatility has created customer inventory overhangs and delayed investment decisions. Recovery expected only once prices stabilize. |
| Freight / input cost pass-through | Elevated ocean freight cannot be fully recovered; customer-specific surcharges cover only part of the increase, and competitive delivered pricing limits recovery. |
| Aquapharm raw material availability | LPG availability constrained Q1 production; raw surcharge assumed removed for the rest of FY27. Vendor diversification and backward integration being evaluated. |
| CBFS tightness & CBO premium | Russian refining outages keep CBFS availability tight; CBO trades ~₹150 higher than CBFS, compressing feedstock economics. Coal tar distillation capex is the planned mitigation. |
Q&A Highlights
Q1 Earnings Quality & Inventory Gains (Aditya – SMIFS)
- Question: How much of the quarter's strength was inventory gains, and why did performance chemicals volumes decline while specialty exports held up?
- Answer: Low-cost inventory gains totaled
₹70 crores, of which ₹40–50 crores may reverse in Q2 (Raj Gupta). Specialty (70% exported) goes to strategic customers who were fully serviced despite supply disruptions; performance chemicals/rubber grades were deliberately redirected to domestic spot markets where margins were better after freight costs eroded export economics (Raj Gupta).
US Tariff Refund (Aditya – SMIFS)
- Question: Have you applied for refunds of US tariffs paid, and how will the amount be recognized?
- Answer: Combined refund across PCBL and Aquapharm is ₹40–45 crores; applications filed and tracked closely, with receipt expected within 2–4 weeks. Accounting treatment (topline vs other income) is under discussion with auditors (Raj Gupta).
Aquapharm EBITDA Sustainability & Exit Run-Rate (Aditya – SMIFS, Sanjesh – ICICI Securities)
- Question: Is the ~₹20/kg EBITDA sustainable, and does the ₹75 crore exit run-rate guidance still hold?
- Answer: Q1 EBITDA/kg of ~₹20,000 vs ₹19,500 in Q1 FY26 is broadly sustainable for the full year, though Q2 may dip on inventory adjustments; capacity utilization remains low, providing upside (Raj Gupta). New CEO Rohit Narang requested a quarter to finalize the turnaround action plan before refreshing detailed guidance (Nilesh Koul, Rohit Narang).
Power EBIT Jump & Nanovace (Aditya – SMIFS)
- Question: Why did power EBIT jump ~₹30 crores QoQ, and what is the Nanovace status?
- Answer: Power realization improved from ₹3.66 to ₹5.39 per unit, driving the EBIT increase (Raj Gupta). Nanovace pilot plant at Palej has consent to operate; equipment trials progressing and line balancing underway; first customer samples expected in August. Management maintains its long-term targets for the battery materials portfolio (Nilesh Koul).
Aquapharm Growth Strategy & Oil & Gas Outlook (Rohit Sinha – Sunidhi Securities)
- Question: Where will Aquapharm volume growth come from — new products, new customers, or new geographies?
- Answer: Phosphonate products are being commercialized over the next three quarters; Tier 1/2 distribution penetration in Europe is driving growth. Oil & gas will remain volatile near-term due to crude swings and customer inventory overhangs, with stabilization expected later in the year. Near-term geography focus is US (New Mexico approvals obtained) and Latin America (Venezuela, Mexico) (Rohit Narang).
Export Mix, Realizations & Logistics (Rohit Sinha – Sunidhi Securities, Kumar – Ambit Capital)
- Question: What was the US/Europe export split, how did realizations move 20%, and how are logistics shaping up?
- Answer: Europe ~16,000 tons and US ~4,800 tons in Q1; new annual contracts being negotiated should drive US growth (Raj Gupta). Realizations rose ~₹27,000 QoQ, of which ~₹12,000 came from better spot pricing/margin and the balance from cost pass-through (Raj Gupta). Logistics remain erratic with elevated prices continuing into Q2; surcharges recover only part of the freight increase (Nilesh Koul).
Carbon Black Volumes, Coal Tar Distillation & CBFS–CBO Spread (Sanjesh – ICICI Securities, Aditya – SMIFS)
- Question: Why did volumes decline despite the Chennai line commissioning, what is the coal tar distillation status, and how did the CBFS–CBO spread behave?
- Answer: Volume was a tactical choice — low-margin international orders were reduced given logistics costs, and low-cost inventory was monetized domestically at new prices (Nilesh Koul). Coal tar distillation business plan is being finalized with OEM supplier discussions; CapEx approval expected this quarter (Nilesh Koul). CBO maintains a ~₹150 premium over CBFS; both moved up together (Raj Gupta).
FY27 Guidance & CapEx (Sanil Jain – Ambit Capital)
- Question: What is the full-year EBITDA/ton guidance and CapEx outlook?
- Answer: Q1 EBITDA/ton was ₹22,900; full-year guidance stands at 14–15% improvement over the FY26 average, implying ~₹16,500–17,000 per ton (Raj Gupta). CapEx is ~₹300 crores ± ₹50 crores, mostly maintenance and efficiency; only ~₹100 crores strategic, with Andhra greenfield spend largely shifting to FY28 (Nilesh Koul).
Volume Growth & Margin Sustainability (Harsh – SKP Securities, Nilesh – HDFC)
- Question: Can the high single-digit volume growth guidance be met, and will margins hold?
- Answer: Yes — Q2 destocking is a timing effect, with growth resuming in Q3–Q4 and export flows from Q2 onwards (Nilesh Koul). Current margins include one-off inventory benefits; structural drivers across US/EU markets, specialty products, and battery materials support multi-year growth, though geopolitical volatility will persist in the near term (Nilesh Koul, Raj Gupta).
Key Takeaway
PCBL Chemical delivered a strong Q1 FY27, with consolidated revenue, EBITDA, and PAT up 17%, 23%, and 65% YoY to ₹2,474 crores, ₹400 crores, and ₹155 crores, aided by ~₹70 crores of low-cost inventory gains as Brent averaged $97/bbl. Carbon black EBITDA per ton hit ₹22,900 versus normalized FY27 guidance of ₹16,500–17,000 per ton, with ₹40–50 crores expected to reverse in Q2. Domestic volumes grew 15% to 102,985 MT while exports (50,528 MT) were deliberately redirected to domestic spot on elevated freight; specialty volumes grew 23% after the 20,000 MTPA Mundra line raised capacity to 900,000 MTPA. Aquapharm delivered ₹394 crores revenue and ₹47 crores EBITDA, with new CEO Rohit Narang targeting volume-led growth. Strategy centers on India's trade-agreement tailwinds, US tariff advantage, Russian supply contraction, a ₹200–250 crore cost-savings program, and battery materials (Nanovace sampling from August). Q2 faces temporary destocking, but management remains constructive on H2 FY27.